PolyTherics to collaborate with UCL to develop a new treatment for ‘sticky blood’ syndrome
PolyTherics Limited announced a new collaboration with Professor Anisur Rahman at UCL (University College London), to use its proprietary site-specific PEGylation to develop a treatment for antiphospholipid syndrome. Professor Rahman and his team have been awarded a 5-year grant of nearly £700,000 from arthritis Research UK to support the work.
Antiphospholipid syndrome (APS), also known as ‘sticky blood’ syndrome, is an autoimmune disease that particularly affects young people and causes blood clots, strokes or recurrent miscarriages. It occurs more commonly in patients with autoimmune rheumatic diseases such as systemic lupus erythematosus. Patients with APS have antibodies to their own phospholipid which bind to phospholipid-protein complexes in the body. This is thought to trigger changes that affect blood clotting. There is no cure for APS; patients are sometimes given anti-coagulant drugs to prevent blood clots but these can have serious side effects.
Professor Rahman and the UCL team have developed proteins that block the binding of anti-phospholipid antibodies to phospholipid-protein complexes in the bloodstream. The next step is to improve the characteristics of these proteins so that they circulate in the body for longer whilst retaining their ability to block this binding. PolyTherics’ proprietary site-specific PEGylation technology is designed to achieve this and its scientists will work closely with the UCL team to produce PEGylated versions of the proteins, which will then be tested by Professor Rahman’s group.
Other news from the department science

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Last viewed contents

A taste for plastic - Discovered for the first time: New deep-sea enzyme breaks down PET plastic

From smoky skies to a green horizon: Scientists convert fire-risk wood waste into biofuel - A simplified new process transforms wood waste from agriculture and forest management into ethanol
Generex Awarded New Patent in Morocco

Images of antibodies working together against malaria

Chemie.DE Information Service's 10th Anniversary: an Online Success Story
Evocatal GmbH Closes New Financing Round

Eppendorf opens new site in Singapore - Targeted strengthening of customer focus with high-tech laboratory for pipette calibration and extensive range of high-quality laboratory services

Evotec enters partnership with Vienna start-up - Quantro exploits innovative functional-genetic and transcriptomic technologies to address “undruggable” targets

BluCon Biotech and LG Chem enter into unique investment agreement - BluCon Biotech's technology has the potential to be a disruptive game changer in the world's plastics market
